EU HTA Regulation: Industry’s Missed Opportunity & The PICO Process

Pharmaceutical companies missed a big opportunity to help shape the scoping process for the forthcoming EU-level joint clinical assessments, but they can still contribute to how the process develops, according to Niklas Hedberg, formerly chair of the recently concluded European Network for Health Technology Assessments.

Close-up of European Names on Maps
Industry can still contribute to developing the scoping system for the EU-level joint clinical assessments • Source: Shutterstock

Companies concerned about European countries using PICO (population, intervention, comparator, outcomes) surveys to help frame the parameters of the EU-level joint clinical assessments (JCA) that will be conducted under the Health Technology Assessment (HTA) Regulation should rest assured.

More from Europe

More from Geography